NANATINOSTAT WITH OR WITHOUT VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMA (NAVAL-1 STAGE 1)
M Lacerdaa,b, R Nairc, H Changd, N Goldschmidte, B Haverkosf, H Huag, L Zinzanih, D Stricklandi, E Gonzálezj
a Universidade da Região de Joinville (UNIVILLE), Joinville, Brazil
b Centro de Hematologia e Oncologia, Joinville, Brazil
c Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, United States
d Division of Hematology, Chang Gung University, Taoyuan, Taiwan
e Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
f Division of Hematology, University of Colorado, Denver, United States
g Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
h Department of Medicine and Surgical Services, University of Bologna, Bologna, Italy
i Viracta, Inc., Cardiff, United States
j Department of Hematology, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain
Ver másLido
432
Vezesque se leu este artigo
142
Total PDF
290
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 11 | 29 |
| 2025 5 | 39 | 6 | 45 |
| 2025 4 | 32 | 8 | 40 |
| 2025 3 | 48 | 14 | 62 |
| 2025 2 | 40 | 17 | 57 |
| 2025 1 | 31 | 12 | 43 |
| 2024 12 | 25 | 20 | 45 |
| 2024 11 | 37 | 31 | 68 |
| 2024 10 | 20 | 23 | 43 |
